Fibroblasts are the basis of Fibrocell’s personalized cell and gene therapy platform because they are the most common cell in skin and connective tissue and are responsible for synthesizing extracellular matrix proteins, including collagen, that provide structure and support.
Fibroblasts are present in all skin and connective tissue.
Fibroblasts can be isolated from the skin and grown in culture. The ability to genetically modify fibroblasts has been well documented in scientific literature.
Fibroblasts synthesize the structural framework of tissue.
Fibroblasts have unique capabilities for localized (vs. systemic) delivery to gene targets in the skin and connective tissue.
Our entire fibroblast platform is done autologously. This approach allows us to avoid many of the rejection concerns presented with allogeneic cells and results in a higher likelihood of efficacy.”
— John Maslowski, Chief Executive Officer
Fibrocell’s autologous fibroblast technology uses our patented manufacturing process, which involves collecting small skin biopsies from patients, isolating cells and expanding them in culture, transducing the fibroblast cells with an integrative lentiviral vector to express a targeted protein, followed by continued expansion of the gene-modified cells in culture. In this manner, each patient is treated with cells that were cultivated from his or her own dermal tissue (i.e., autologous). Fibrocell is developing its gene-therapy product candidates in collaboration with Intrexon Corporation (NYSE: XON), a leader in synthetic biology.